Cephalochromin, a FabI-directed antibacterial of microbial origin

Biochemical and Biophysical Research Communications

Volumn 362, Issue 4, 2007, Pages 1107-1112

  Zheng, Chang Ji ^a   Sohn, Mi Jin ^a   Lee, Sangku ^a   Hong, Young Soo ^a   Kwak, Jin Hwan ^b   Kim, Won Gon ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Handong University   (South Korea)

Author keywords

Antibacterial; Cephalochromin; Enoyl ACP reductase; FabI; Fatty acid synthesis; Naphtho pyrone

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEPHALOCHROMIN; CEPHALOCHROMIN HEXAMETHYL ETHER; CEPHALOCHROMIN TRIMETHYL ETHER; CHLORAMPHENICOL; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ETHER DERIVATIVE; FATTY ACID; METHYL GROUP; NAPHTHYL GROUP; PROTEIN FABI; PYRONE DERIVATIVE; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL STRAIN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ESCHERICHIA COLI; FATTY ACID SYNTHESIS; IC 50; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; WILD TYPE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME ACTIVATION; ESCHERICHIA COLI PROTEINS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

EID: 34548593708     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.144     Document Type: Article

References (25)

1. Campbell J.W., and Cronan J.E. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55 (2001) 305-332
2. Heath R.J., and Rock C.O. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs 5 (2004) 146-153
3. Zhang Y.-M., White S.W., and Rock C.O. Inhibiting bacterial fatty acid synthesis 281 (2006) 17541-17544
4. McMurry L.M., Oethinger M., and Levy S.B. Triclosan targets lipid synthesis. Nature 394 (1998) 531-532
5. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., and Rock C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274 (1999) 11110-11114
6. Rozwarski D.A., Grant G.A., Barton D.H.R., Jacobs Jr. W.R., and Sacchettini J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279 (1998) 98-102
7. Heerding D.A., Chan G., DeWolf Jr. W.E., Fosberry A.P., Janson C.A., Jaworski D.D., Mcmanus E., Miller W.H., Moore T.D., Payne D.J., Qiu X., Rittenhouse S.F., Radosti C.S., Smith W., Takata D.T., Vaidya K.S., Yuan C.C.K., and Huffman W.F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier reductase (FabI). Bioorg. Med. Chem. Lett. 11 (2002) 2061-2065
8. Miller W.H., Seefeld M.A., Newlander K.A., Uzinskas I.N., Burgess W.J., Heerding D.A., Yuan C.C.K., Head M.S., Payne D.J., Rittenhouse S.F., Moore T.D., Pearson S.C., Berry V., DeWolf Jr. W.E., Keller P.M., Polizzi B.J., Qiu X., Janson C.A., and Huffman W.F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 45 (2002) 3246-3256
9. Payne D.J., Miller W.H., Berry V., Brosky J., Burgess W.J., Chen E., DeWolf Jr. W.E., Fosberry A.P., Greenwood R., Head M.S., Heerding D.A., Janson C.A., Jaworski D.D., Keller P.M., Manley P.J., Moore T.D., Newlander K.A., Pearson S., Polizzi B.J., Qiu X., Rittenhouse S.F., Slater-Radosti C., Salers K.L., Seefeld M.A., Smyth M.G., Takata D.T., Uzinskas I.N., vaidya K., Wallis N.G., Winram S.B., Yuan C.C.K., and Huffman W.F. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46 (2002) 3118-3142
10. Ling L.L., Xian J., Ali S., Geng B., Fan J., Mills D.M., Arvanites A.C., Orgueira H., Ashwell M.A., Carmel G., Xiang Y., and Moir D.T. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents Chemother. 48 (2004) 1541-1547
11. Seefeld M.A., Miller W.H., Newlander K.A., Burgess W.J., DeWolf Jr. W.E., Elkins P.A., Head M.S., Jakas D.R., Janson C.A., Keller P.M., Manley P.J., Moore T.D., Payne D.J., Pearson S., Polizzi B.J., Qiu X., Rittenhouse S.F., Uzinskas I.N., Wallis N.G., and Huffman W.F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 46 (2003) 1627-1635
12. Zhang Y.-M., and Rock C.O. Evaluation of epigallocatechin gallate and related plat polyphnols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J. Biol. Chem. 279 (2004) 30994-31001
13. Tasdemir D., Lack G., Brun R., Ruedi P., Scapozza L., and Perozzo R. Inhibition of Plasmodium falsiparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI and drug targets for flavonoids. J. Med. Chem. 49 (2006) 3345-3353
14. Moir D.T. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 5 (2005) 297-305
15. Singh M.P., and Greenstein M. Antibacterial leads from microbial natural products discovery. Curr. Opin. Drug Discov. Develop. 3 (2000) 167-176
16. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y.S., Cummings R., Ha S., Dorso K., Motyl M., Jayasuriya H., Ondeyka J., Herath K., Zhang C., Hernandez L., Allocco J., Basilio A., Tormo J.R., Genilloud O., Vicente F., Pelaez F., Colwell L., Lee S.H., Michael B., Felcetto T., Gill C., Silver L.L., Hermes J.D., Bartizal K., Barrett J., Schmatz D., Becker J.W., Cully D., and Singh S.B. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006) 358-361
17. Koyama K., and Natori S. Further characterization of seven bis(naphtha-γ-pyrone) congeners of ustilaginoidins, coloring matters of Claviceps virens (ustilaginoidea virens). Chem. Pharm. Bull. 39 (1998) 146-152
18. Matsumoto M., Minato H., Kendo E., Mitsugi T., and Katagiri K. Cephalochromin, dihydroisoustilaginoidin A, and iso-ustilaginoidin A from Verticillium sp. K-113. J. Antibiot. 28 (1975) 602-604
19. Zheng C.J., Yoo J.S., Lee T.G., Cho H.Y., Kim Y.H., and Kim W.G. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett. 579 (2005) 157-5162
20. Kwak J.H., and Weisblum B. Regulation of plasmid pE194 replication: control of cop-repF operon transcription by Cop and of repF translation by countertranscript. J. Bacteriol. 176 (1994) 5044-5051
21. Kraemer G.R., and Iandolo J.J. High frequency transformation of Staphylococcus aureus by electroporation. Curr. Microb. 21 (1990) 373-376
22. Slater-Radosti C., Van-Aller G., Greenwood R., Nicholas R., Keller P.M., DeWolf Jr. W.E., Fan F., Payne D.J., and Jaworski D.D. Biochemical and genetic characterisation of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48 (2001) 1-6
23. Hegde V.R., Miller J.R., Patel M.G., king A.H., Puar M.S., Horan A., Hart R., Yarborough R., and Gullo V. Sch 45752-an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J. Antibiot. 46 (1993) 207-213
24. Ishi R., Horie M., Koyama K., Ishikawa Y., and Kitanaka S. Inhibitory effects of fungal bis(naphtha-γ-pyrone) derivatives on nitric oxide production by a murine macrophage-like cell line, Raw 264.7, activated by lipopolysaccharide and interferon-γ. Biol. Chem. Bull. 28 (2005) 786-790
25. Sivaraman S., Zwahlen J., Bell A.F., Hedstrom L., and Tonge P.J. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. Biochemistry 42 (2003) 4406-4413